506 Oral metronomic cyclophosphamide in recurrent ovarian cancer: a single centre experience

Abstract

<h3>Introduction/Background</h3> Oral metronomic cyclophosphamide (OMC) consists in the chronic administration of low, usually daily, doses of chemotherapy. The effective reduction of tumour growth, oral administration, low toxicity profile and low cost benefit women with relapsed ovarian cancer, especially heavily pretreated patients. We retrospectively evaluated the outcome of patients treated with OMC for recurrent ovarian cancer. <h3>Methodology</h3> We selected patients treated with OMC (50 mg daily) from 2016 to 2020 at the Academic Department Gynaecology, Mauriziano Hospital, Torino, Italy. Progression free survival (PSF) and toxicities profile were evaluated. <h3>Results</h3> Thirty-five patients were analyzed. 28 (87%) had FIGO stage III and IV disease at diagnosis and 59% had received ≥ 4 previous lines. Average age was 68 years (range 47–88). Before starting OMC 16% had ECOG 0, 65% ECOG 1 and 19% ECOG 2. Median PFS was 5 months. PFS was ≥ 6 months in 33% of patients, ≥ 12 months in 13% and ≥ 18 months in 7%. 52% experienced clinical benefit in terms of symptoms reduction. 3% of discontinuation for side effects and no G3-4 hematological toxicities reflected a low toxicity profile. Only nausea and fatigue G1-G2 were reported in 4 (12%) and 9 (28%) cases, respectively. <h3>Conclusion</h3> OMC could be a feasible alternative therapy for recurrent ovarian cancer leading to an acceptable clinical response with a low toxicity profile, even if patients are heavily pretreated and with a suboptimal performance status. <h3>Disclosures</h3> Authors have no conflict of interest.